IMNM - Immunome Inc

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.

52W High

$16.73

52W Low

$5.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.92

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.72

EV/Revenue (<3 favorable)

51.78

P/S (TTM) (<3 favorable)

72.74

P/B (<3 favorable)

3.40

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

11.47%

Institutions (25–75% balanced)

86.84%

Shares Outstanding

87,045,000

Float

70,809,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

12,589,000

Gross Profit (TTM)

-120,196,000

EPS (TTM)

-3.05

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-11.58%

ROE (TTM) (>15% strong)

-0.81%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.70

Momentum

Bearish momentum

Value

-0.2170

-0.1852

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025